Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

Tuesday, September 16, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has reported encouraging results for its oral drug candidate, Ketamir-2, which has shown the ability to restore normalized behavior in stressed animals. This development marks a significant step as the company expands its focus from neuropathic pain to neuropsychiatric disorders, including PTSD. The positive data reinforces the potential of Ketamir-2 in treating these conditions.
Price reaction · baseline $1.38 (2025-09-15 close) · hit pre-market · clean, no other MIRA news in the window
day 0 close
-5.1%
day 1
-6.5%
day 3 · peak
-9.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • MIRA Pharmaceuticals reports positive data for Ketamir-2.
  • Ketamir-2 demonstrated the ability to restore normalized behavior.
  • The drug is advancing in clinical development for PTSD.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~21 mo
Low dilution risk

Full Press Release Details

MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD MIAMI, FLORIDA / ACCESS Newswire / September 16, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive results demonstrating that its oral drug candidate Ketamir-2 restored nor…
You can read the full content here

Frequently Asked Questions

What is Ketamir-2?

Ketamir-2 is an oral drug candidate developed by MIRA Pharmaceuticals for neuropsychiatric disorders.

What positive results were reported?

MIRA reported that Ketamir-2 restored normalized behavior in stressed animals.

What disorders is MIRA targeting with Ketamir-2?

MIRA is targeting neuropsychiatric disorders, including PTSD and neuropathic pain.

When was the positive data announced?

The positive data for Ketamir-2 was announced on September 16, 2025.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals Ketamir-2 PTSD neuropathic pain neuropsychiatric disorders
Last updated: Sep 16, 2025

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
~21 mo
Low dilution risk

Catalyst track record

+5%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →